MAPT and Alzheimer disease: We observed that GAGs extracted from the AD brain presented a significantly higher capacity to bind to tau compared to GAGs from control tissue (Fig 5a), as translated by the GAGs concentration necessary to inhibit 50% of tau binding to the immobilized heparin (Fig 5b).